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The diagnostic and monitoring value of serum anti-mutated citrullinated 
vimentin antibodies (anti-MCV) in juvenile rheumatoid arthritis  
 
INTRODUCTION 
Juvenile rheumatoid arthritis (JRA) is a common 
rheumatic disease of children that begins before the 
age of 16 years. It is a major cause of chronic 
disability characterized by synovitis of the 
peripheral joints and associated with soft tissue 
swelling and effusion resulting in loss of joint 
functions and morbidity1.JRA is currently 
diagnosed using the American College of 
Rheumatology (ACR) 1987 revised criteria that are 
primarily based on clinical parameters, the only 
serological criteria being IgM rheumatoid factor 
(RF). Rheumatoid factors sensitivities and 
specificities for discrimination of RA from non-RA 
vary in different studies with a report of a mean 
specificity of only 79%, and sensitivity of 60%2. 
Moreover, several studies have shown that only 5% 
to 25% of children with juvenile rheumatoid 
arthritis have positive latex agglutination tests for 
RF. So the diagnostic importance of RF in a child 
with possible chronic arthritis is of little utility3. 
Identification of autoantigens containing the 
amino acid citrulline in adult RA is considered one 
of the most important serological discoveries in 
rheumatology in recent years, as they can be 
detected years before the onset of RA and reach a 
specificity of more than 95%4. This family of 
autoantibodies is an overlapping group of 
antibodies dependent on the citrullination of 
arginine residue. It includes antiperinuclear factor 
(APF), antikeratin antibody (AKA), antifilaggrin 
antibodies (AFA), anti-Sa (vimentin), and anti-
cyclic citrullinated peptide (CCP) antibodies5. 
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Vimentin, one of the intermediate filaments, is 
a 58 kD protein.  Vimentin is a Latin word which 
means arrays of flexible rods. Immuno-
histochemical staining revealed vimentin filaments 
as part of a wavy network of filaments in the 
cytoplasm of fibroblasts, associated with both 
nuclear and plasma membranes6. Vimentin isoforms 
were identified in which arginine residues were 
replaced by glycine, which they named mutated 
citrullinated vimentin. So, vimentin is usually not in 
a citrullinated state, but deimination of this protein 
occurs in macrophages undergoing apoptosis by 
Peptidylarginine deiminase enzyme(PAD)7.  In 
addition, vimentin was found to represent a 
predominant substrate of PAD enzymes family, 
especially in activated and dying macrophages in 
patients with RA8. 
Some studies showed that anti-MCV antibody 
is more sensitive compared to other antibodies 
against citrulline-containing epitopes for RA 
diagnosis9, and that anti-MCV antibody was present 
even earlier in the course of RA than anti-CCP, and 
therefore was a better marker of early RA10.Besides 
the higher sensitivity it has been shown that anti-
MCV antibody is a better marker for early RA, and 
it correlates well with the disease activity score 
(DAS).  The presence of anti-MCV antibodies at 
disease onset is associated with a more severe 
disease course, measured as higher level of 
inflammatory activity compared with anti-CCP7. 
This work was aimed to evaluate the role of 
anti-mutated citrullinated vimentin antibodies (anti-
MCV) in diagnosis and for monitoring disease 
activity in juvenile rheumatoid arthritis. 
 
METHODS 
This case control study was carried out at the 
Pediatric Allergy and Immunology unit, Children's 
Hospital, Ain Shams University. An informed 
consent was obtained from the parents or care-
givers of patients and controls before enrollment. 
The study protocol was approved by the ethics 
committee of the Department of Pediatrics, Ain 
Shams University.  
A) Patients' Group: It comprised 40 children with 
JRA fulfilling the American College of 
Rheumatology criteria for diagnosis of JRA11. Four 
children had oligoarticular , 12 had polyarticular  
and 24 had systemic onset type. They were 18 
males and 22 females. Their ages ranged from 2-18 
years with a median of 9.5 years and their disease 
duration ranged from 5 months to 15 years with a 
median of 2.6 years.  
B) Control group: Fifty healthy age and sex 
matched to the patients children comprised the 
control group. They were 22 males and 28 females; 
their ages ranged from 1-16 years with a median of 
8.3 years. 
Clinical Methods: 
The studied children with JRA were subjected to 
medical history taking, laying stress on age of 
onset, onset type, disease duration, symptoms of 
active disease and current medications. Clinical 
examination was done with record of number of 
tender and/or swollen joints and current activity of 
systemic manifestations (fever or skin rashes)12.        
Laboratory methods: 
Eight mL of peripheral venous blood were 
withdrawn aseptically from each patient and 3 mL 
from each control subject. Three mL blood were 
left to clot for 15 minutes then centrifuged and sera 
were put into aliquots and stored at -20oC until 
assayed for anti-MCV antibodies for both patients 
and controls. The remaining 5 ml were used for 
other investigations done to patients: 
i. Complete blood picture using coulter counter.  
ii. Measurement of ESR by the Westergren 
method. 
iii. Measurement of CRP by latex agglutination test. 
iv. Measurement of serum rheumatoid factor by 
latex agglutination test. 
v.  Measurement of ANA by indirect immune-
fluorescence technique. 
Measurement of serum anti-MCV antibodies: 
This was done using an indirect solid phase enzyme 
immunoassay (ELISA) kit for the quantitative 
measurement of IgG class autoantibodies against 
mutated citrullinated vimentin (MCV) in human 
serum (The kit was provided by ORGENTEC 




Statistical analysis was done using SPSS software 
package, version 15.0, 2006, Ecosoft corporation, 
USA. Data was expressed descriptively as median 
and interquartile range for quantitative skewed data 
and qualitative data were expressed as percentage. 
Comparison between groups was done using 
Wilcoxon's rank sum test and Chi square test.  
Correlation study between the different analyzed 
parameters was done using Spearman's rank 
correlation coefficient test. Furthermore, the 
diagnostic performance of anti-MCV antibodies 
was evaluated using receiver operating 
characteristic curve (ROC) analysis. The best cutoff 
value (the point nearest to the left upper corner of 
the curve) was determined. For all tests a 
probability (P) less than 0.5 was considered 
significant. 
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RESULTS 
Serum anti-MCV levels of JRA patients ranged 
from 5 to 1000 u/mL (Median = 26.5 u/mL). These 
values were significantly higher than the 
corresponding values of the control group in whom 
the level ranged from 2 to 40 (Median = 10 u/ml) as 
shown in figure (1). 
Serum levels of anti-MCV correlated 
positively yet insignificantly with age, onset of 
JRA, duration of the disease, number of tender 
joints, hemoglobin concentration and ESR. (rs = 
0.259, 0.136, 0.201, 0.143, 0.135, 0.019  
respectively P>0.05). They correlated negatively 
with the number of swollen joints, platelets, WBCS 
and CRP (rs = -0.043, -0.127, -0.093, -0.074 
respectively P>0.05) in JRA patients . 
The receiver operating characteristic (ROC) 
curve, plotted to assess the diagnostic performance 
of serum anti-MCV antibody in JRA patients 
revealed that the area under the curve (AUC) was 
(0.896) and the optimum cutoff level was (>17 
u/mL) (Figure 2). The analysis revealed that serum 
anti-MCV antibody level had diagnostic specificity 
of 88%, diagnostic sensitivity of (87.5%), both 
negative and positive predictive values of (89.8% 
and 85.4%, respectively) and diagnostic efficacy of 
(87.8%) (Table 1).Based on this cut off level the 
frequency of elevated anti-MCV antibody level was 

















Figure 1. Serum anti-MCV antibody levels (U/mL) 
in JRA patients versus controls. 
 
With respect to disease onset type, we found 
that serum anti-MCV antibody was elevated in 
20/24 (83.3%) of those with systemic onset type, in 
9/12 (75%) of those with the polyarticular onset 
type and in 4/4 (100%) of those with the 
pauciarticular onset type. The differences were 
statistically insignificant (p=0.51).   
We found that among patients with elevated 
antibody level, 2/33 (6.1%) patients were RF 
positive in comparison to 1/7 (14.3%) in the group 
of patients with normal antibody level. As regards 
ANA the frequency was 2/33 (6.1%) and 0/7 
(0.0%) respectively. However, there was no 
significant variation in anti-MCV level with RF and 
ANA negativity or positivity. 
No significant differences were observed in 
anti MCV antibody positivity among JRA patients 
with respect to corticosteroid therapy, as the 
percentage of those on steroid therapy who were 
anti MCV positive was comparable to those who 
were not using corticosteroids (p = 0.268). Similar 
findings were found as regards non-steroidal anti- 
inflammatory drugs and methotrexate. 
Similarly, clinical and laboratory markers of 
disease activity (namely, number of swollen joints, 
number of tender joints, CRP and ESR) were 
comparable in patients with elevated and those with 
normal serum anti MCV antibody level. However, 
positive correlations were observed between serum 
anti- MCV antibody and patient’s age, duration of 
illness, number of tender joints, and ESR, although 
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AUC = 0.896 
 
Figure 2. ROC curve analysis showing the 
diagnostic performance of anti-MCV antibody. 
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DISCUSSION 
As limited numbers of serological laboratory tests 
are helpful for the classification, diagnosis and for 
evaluating the clinical status of JRA, continuing 
efforts are made to find more sensitive and specific 
markers for diagnosis of JRA. Autoantibodies 
against citrullinated peptide antigens (ACPA) have 
been described in RA diagnosis. The newest 
member of this autoantibody family is anti-mutated 
citrullinated vimentin (MCV)5. 
The present study revealed a significantly 
higher serum anti- MCV antibody level in JRA 
patients when compared to healthy controls (mean 
of 158.43 versus 11.98 u/ml respectively). This can 
be explained by the hypothesis that vimentin might 
trigger the intial immune response in RA13. It 
activates T-lymphocytes by binding on HLA- DR4 
on the surface of antigen presenting cells and may 
contribute to certain pathways in the pathogenesis 
of RA. This comes in accordance with many 
previous studies5,7,8,15 all of which reported a 
significant elevation in serum anti-MCV in RA 
patients versus controls.  
However other researches16,17,18 failed to find 
this significant difference, a finding which can be 
explained by the fact that vimentin contains 43 
arginine residues with 10 citrullination sites 
experimentally confirmed and anti-MCV antibodies 
are considered a heterogenous group of antibodies 
directed against different epitopes on the citrulline 
molecule7.  
In a trial to assess the diagnostic performance 
of serum anti MCV antibodies in JRA, the ROC 
curve was plotted. We found that at a cut off value 
of 17 u/ml serum anti MCV antibody had a 
specificity and a sensitivity of 88% and 87.5% 
respectively and the negative and positive 
predictive values were 89.8% and 85.4% 
respectively, with a diagnostic efficacy of 87.8%. 
At a cut of value of 20 u/ml, Poulsom and Charles15 
found a specificity and sensitivity of 87% and 84% 
respectively, while Dejaco and associates19 reported 
a result of 90.8% and 69.5% respectively. However, 
at a cut off value of 25 u/ml, Bang and colleagues7 
reported the specificity and sensitivity to be 88% 
and 82% respectively.  
Variation in the sensitivity and specificity can 
be attributed to the fact that some of the studies 
included patients with enthesitis-related arthritis, 
undifferentiated arthritis and psoriatic arthritis 
depending on the new classification of RA in 
children, the International League of Associations 
For Rheumatology (ILAR) classification of JIA 
which represents an umbrella term for a group of 
heterogenous, chronic inflammatory diseases of 
unknown etiology20. 
Our study could not demonstrate a significant 
value for serum anti MCV antibody in diagnosis of 
active disease status in JRA as there was no 
significant difference between patients with 
elevated and normal antibody level as regards 
number of swollen and tender joints, ESR and CRP. 
This was in spite the presence of positive 
correlations between the antibody level, ESR, 
duration of illness and number of tender joints. The 
small sample size as well as the facts that serum 
anti MCV antibody was not measured at diagnosis, 
but during routine follow- up visits in the 
specialized clinic and were not compared in the 
same patient at different statuses of the disease offer 
explanation for the lack of significant relation to 
disease activity. This finding was supported by 
previous studies5,10.  
On the other hand, multiple researches7,8,14,21, 
succeeded to show a significant elevation in clinical 
and laboratory disease parameters in patients with 
elevated serum anti MCV antibody. Innala and 
associates22 reported that in patients with early RA, 
persistent inflammatory activity, measured by the 
DAS28, ESR, CRP and swollen joint count were 
identified best by anti-MCV antibody compared to 
other ACPA. A significant decrease in anti-MCV 
level concentration corresponded to the therapeutic 
response.     
In our study, the type of disease onset had no 
impact on serum anti-MCV antibody as there was 
no significant difference in the antibody level 
among patients with polyarticular, oligoarticular or 
systemic disease onset (P 0.515). However, 
Morbach and associates18 found significantly 
increased frequencies of anti-MCV positive patients 
among polyarticualr RA with increased specificity 
as compared to other rheumatoid subgroups.  
The results of the present study provide 
preliminary evidence that there was no association 
between serum anti-MCV antibody and the 
presence of positive RF or ANA based on the 
findings in our patients. Several studies 23 have 
Anti MCV in juvenile rheumatoid arthritis. 
  79
shown that only 5% to 25% of children with JRA 
have positive latex agglutination for RF. Children 
with high titers of RF likely represent a subgroup 
distinct from the larger number of children with 
seronegative disease 3. Although positive ANA tests 
are sometimes seen in children with JRA, they are 
not distinguishing feature of the disease and they 
reach their highest prevalence (65%-85%) in 
children with oligoarthritis and uveitis 3.  
Strange enough, we could not elicit in our 
study a significant link between serum anti-MCV 
antibody and drug therapy. This comes in 
agreement with Poulsom and Charles 15 who 
reported that there was no statistically significant 
change in the antibody level in patients treated with 
methotrexate alone or a combination of 
methotrexate and interferon over a longitudinal 
study covering four time points (pretreatment, 6, 18 
and 52 weeks). On the other hand, Mathsson and 
associates 8 found that serum anti-MCV antibody 
level declined significantly with treatment during 
the first study year.  
Serum anti-MCV antibody could be a 
promising tool in diagnosing JRA, however it failed 
to show a significant link with disease activity or 
the type of disease onset. Serum anti-MCV 
antibody should be studied in a larger sample 
including different entities of chronic arthritis in 
childhood and at different time points of the disease 
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